Open AccessEFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Author(s) -
Paul Mitchell,
Frank G. Holz,
Philip Hykin,
Edoardo Midena,
Eric H. Souied,
Helmut Allmeier,
George N. Lambrou,
Thomas Schmelter,
Sebastián Wolf,
Aries study investigators
Publication year - 2021
Publication title -
retina
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.24
H-Index - 120
eISSN - 1539-2864
pISSN - 0275-004X
DOI - 10.1097/iae.0000000000003128
Subject(s) - aflibercept , medicine , macular degeneration , visual acuity , choroidal neovascularization , ophthalmology , confidence interval , diabetic retinopathy , randomization , randomized controlled trial , surgery , bevacizumab , diabetes mellitus , chemotherapy , endocrinology
Treating neovascular age-related macular degeneration with intravitreal aflibercept treat-and-extend (T&E) can reduce treatment burden. ARIES assessed whether intravitreal aflibercept early-start T&E was noninferior to late-start T&E.